Evidence of sustained benefits of pimavanserin for dementia-related psychosis

(University of Exeter) A new paper published in the New England Journal of Medicine outlines a clinical trial, conducted in 392 people with psychosis associated with Alzheimer's disease, Parkinson's disease, Lewy body, frontotemporal, or vascular dementia. All participants were given pimavanserin for 12 weeks. Those who met a threshold of symptom improvement were then assigned to pimavanserin or placebo for up to 26 weeks.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news